Compare Eli Lilly And Co (LLY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Materials Select Sector SPDR Fund — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Eli Lilly And Co is far larger — about 134.5× Materials Select Sector SPDR Fund's market cap, and Eli Lilly And Co pays a 0.59% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| LLY | XLB | |
|---|---|---|
Market Cap | $1.04T | $7.73B |
Volume | 3,064,878 | 13,681,146 |
Sector | Health | — |
52-Week High | $1.28K | $53.67 |
52-Week Low | $799.57 | $42.23 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
XLB trades at $49.27 with a slight 0.59% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets and top 10 holdings at 59% exposure. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
The outlook remains cautious with technical weakness outweighing fundamental support. Investment opportunity exists in long-term materials exposure through efficient, low-cost ETF structure, but risks include sector concentration, cyclical pressures, and competition from AI-focused investments. Current levels near key support at $48-$49 require monitoring for potential breakdown.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
